Bioverativ Inc

Bioverativ — Investor Day (January 2017)

50 slides from Bioverativ's investor day presentation, Jan 6, 2017

  1. Slide 1: Bioverativ Investor Day

    Bioverativ Investor Day January 6th, 2017 Confidential and proprietary

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements • This presentation contains forward-looking statements, including statements relating to: the planned separation of Bioverativ from Biogen; business and strategic objectives; growth prospects and potential opportunities for commercial products and pipeline programs; plann

  3. Slide 3: Today's Agenda

    Today’s Agenda Time Topic Speaker Paul Clancy 10:05-10:10am Introduction Biogen CFO Investment John Cox 10:10-10:50am opportunity and Chief Executive Officer strategic vision Global Rogerio Vivaldi, MD, MBA 10:50-11:10am Therapeutic Chief Global Therapeutic Operations Operations Officer Financial Jo

  4. Slide 4: Welcome

    Welcome Paul Clancy, Biogen CFO

  5. Slide 5: Investment opportunity and strategic vision

    Investment opportunity and strategic vision John Cox, CEO

  6. Slide 6: Our Vision is to become the leading hematology rare disease company

    Our Vision is to become the… leading hematology rare disease company committed to creating significant progress for patients Confidential and proprietary 6

  7. Slide 7: A Unique and Compelling Investment Opportunity

    A Unique and Compelling Investment Opportunity Integrated Strong hemophilia Capitalized to Talented team capabilities franchise create value Confidential and proprietary 7

  8. Slide 8: Bioverativ: Why Compelling?

    Bioverativ: Why Compelling? Expected revenues of >$800 million in 2016 targeting a $10B+ market in hemophilia Generated $203 million of net cash flows from operations from Q1-Q3 2016 Geographic presence in U.S., Japan, and Canada with opportunities to expand R&D, clinical development, regulatory pro

  9. Slide 9: Positioned for Growth as a Stand Alone Company

    Positioned for Growth as a Stand Alone Company Pursue Strategic Rapidly Opportunities Advance our Maximize Discovery Potential of Molecules ELOCTATE & ALPROLIX Strong Hemophilia Capitalized to Create 9 Integrated Capabilities Talented Team Confidential and proprietary Franchise Value

  10. Slide 10: Accomplished and Driven Executive Leadership Team

    Accomplished and Driven Executive Leadership Team John Cox John Greene Rogerio Vivaldi, MD, MBA Chief Executive Officer Chief Financial Officer Chief Global Therapeutic Operations Officer Richard Brudnick Lucia Celona Andrea DiFabio EVP of BD & Alliance Chief HR & Corporate Chief Legal Officer Manag

  11. Slide 11: Strong Scientific, Medical Leaders with Hematology Expertise

    Strong Scientific, Medical Leaders with Hematology Expertise Maha Radhakrishnan, M.D. SVP, Medical Rob Peters, Ph.D. 12+ years in Medical Affairs leadership SVP, Research roles at BMS, Cephalon and Biogen. 16+ years experience. Global experience, most recently Europe Renowned hemophilia scientist. M

  12. Slide 12: A Unique and Compelling Investment Opportunity

    A A Unique Unique and and Compelling Compelling Investment Investment Opportunity Opportunity Integrated Strong Hemophilia Capitalized to Talented team capabilities Franchise create value Strong Hemophilia Capitalized to Create 12 Integrated Capabilities Talented Team Confidential and proprietary Fr

  13. Slide 13: Our Therapies; First Innovation in Years

    Our Therapies; First Innovation in 20 Years Next Generation Therapies Recombinant Novel Bispecific Gene Extended EHLs Abs Therapy Industry Evolution Half-Life Factors (Future) Plasma-Derived Recombinant Clotting Factors Clotting Factors Conventional (2014–present) or “short-acting” (1969–present) (1

  14. Slide 14: Hemophilia is a $10B+ Global Market, Growing at 7%

    Hemophilia is a $10B+ Global Market, Growing at 7% Opportunity for growth within each market segment Hemophilia A&B Factor Market: Growing Hemophilia Market: ~$10B Globally Hemophilia A • Prevalent population increasing globally ~151k identified patients ~80% of Hemophilic Population ~$8bn Global Ma

  15. Slide 15: ELOCTATE & ALPROLIX Have Delivered Strong Uptake Since Launch

    ELOCTATE & ALPROLIX Have Delivered Strong Uptake Since Launch and are Approaching $800M+ in 2016 Hemophilia Product Revenue ($mm) Q1-Q3 2016: $605M 205 217 172 183 156 129 77 97 47 10 Q2-14 Q3-14 Q4-14 Q1-15 Q2-15 Q3-15 Q4-15 Q1-16 Q2-16 Q3-16 Strong Hemophilia Capitalized to Create 15 Integrated Ca

  16. Slide 16: ELOCTATE and ALPROLIX Utilize Proprietary Fc Fusion Technology

    ELOCTATE and ALPROLIX are the Only Factors Utilizing Proprietary Fc Fusion Technology Binding redirects the product back toward the bloodstream, avoiding The Fc portion of the degradation pathways product temporarily binds to receptors in your body The product is released back into the bloodstream w

  17. Slide 17: Potential Opportunities to Address Significant Unmet Medical Needs

    Potential Opportunities to Address Significant Unmet Medical Needs with ELOCTATE and ALPROLIX Immune Tolerance Women with Joint Health Induction Hemophilia • Factor replacement can • Risk of progressive and • Many women with recessive eradicate inhibitors vs extremely debilitating joint gene for hem

  18. Slide 18: A Unique and Compelling Investment Opportunity

    A A Unique Unique and and Compelling Compelling Investment Investment Opportunity Opportunity Integrated Strong Hemophilia Capitalized to Talented team capabilities Franchise create value Strong Hemophilia Capitalized to Create 18 Integrated Capabilities Talented Team Confidential and proprietary Fr

  19. Slide 19: Pipeline of Novel, Next Generation Hemophilia, Beta-Thalassemia, and Sickle Cell Candidates

    Pipeline of Novel, Next Generation Hemophilia, Beta- Thalassemia, and Sickle Cell Disease Candidates Drug Indication Description Modality Discovery Preclinical Clinical Marketed EHL factor BIVV 001 Hem A 1x/weekly dosing Biologic rFVIIIFc-VWF-XTEN or less frequent BIVV 002 EHL factor Hem B Biologic

  20. Slide 20: BIVV 001 Designed to Extend Hemophilia A Prophylaxis

    BIVV 001 Designed to Extend Hemophilia A Prophylaxis to Once Weekly or Less Frequently rFVIIIFc-VWF-XTEN Improved PK Profile of Intravenously Technology Delivered BIVV 001 in Cynomolgus Monkeys Uniquely engineered factor VIII molecule with a region of Fc dimer, FVIII Plasma Level Normalized to Dose

  21. Slide 21: Scientific Rationale for BIVV 001 Molecule Design

    Scientific Rationale for BIVV 001 Molecule Design Novel fusion protein, consisting of: D’D3 domains of VWF provide protection & stability of VWF while evading half-life limitation of endogenous VWF XTEN polypeptides, which improve the pharmacokinetic profile and degrade naturally rFVIII fused to dim

  22. Slide 22: BIVV 002 Designed to Enable Subcutaneous Administration

    BIVV 002 Designed to Enable Subcutaneous Administration rFIXFc-XTEN 50 IU/kg rFIXFc (IV) 100 IU/kg 200 IU/kg Technology 100 IU/kg rFIXFc-XTEN (SC) 200 IU/kg Combines Fc dimer and XTEN technology along with R338L Padua Factor IX variant in the treatment of 140 Hemophilia B 120 60 Potential Clinical P

  23. Slide 23: Molecular Design of BIVV 002

    Molecular Design of BIVV 002 Fc domain for extended half-life XTEN 72 WT WT . R338L catalytic catalytic catalytic EGF EGF EGF EGF EGF EGF GLA GLA GLA R338L (Padua) to enhance FIX activity XTEN peptide for improved bioavailability and extended half-life rFIX rFIXFc rFIXFc-XTEN (BeneFIX) (ALPROLIX) Ac

  24. Slide 24: Collaboration on Sangamo's ZFN-mediated Genome Editing Programs

    Collaboration on Sangamo’s Non-viral, Ex-vivo ZFN-mediated Genome Editing Programs for β-thal, SCD Technology ZFN-mediated Enhancer Knockout Zinc finger nuclease (ZFN)-mediated genome editing program for beta-thalassemia and sickle cell disease is based on the use of genome editing technology to mod

  25. Slide 25: Large Opportunity Exists for Expansion in Rare Hematology

    Large Opportunity Exists for Expansion in Rare Hematology Global Non-Malignant Hematology Market (2016) Additional Rare Hematology Opportunities: HUS Illustrative Hemochromatosis Aplastic Anemia AL Amyloidosis Hemophilia + Essential Thrombocytemia Wiskott- Sickle Cell Disease + Aldrich β-thalassemia

  26. Slide 26: Business Development Vision: Sector Expert and Partner of Choice

    Business Development Vision: Sector Expert and Partner of Choice • Numerous rare hematologic diseases with high unmet need and interesting accessible clinical stage assets • Committed to exploring such opportunities to bolster our pipeline • With our expertise we believe we can drive programs rapidl

  27. Slide 27: Global Therapeutic Operations

    Global Therapeutic Operations Rogerio Vivaldi, MD, MBA

  28. Slide 28: Strategic Imperatives for Therapeutic Operations

    Strategic Imperatives for Therapeutic Operations Maximize Potential of ELOCTATE and ALPROLIX Enhance Value with Patient-Centric Approach Strong Hemophilia Capitalized to Create 28 Integrated Capabilities Talented Team Confidential and proprietary Franchise Value

  29. Slide 29: Patient-Centric Model in Rare Hematology

    Patient-Centric Model in Rare Hematology CoRe Managers Patient Services Work directly with the Provides caregivers, patients community to provide and healthcare providers with educational information, dedicated and individualized resources, and info about our Advocacy support programs and services G

  30. Slide 30: Strong Launches Position ELOCTATE & ALPROLIX for Future Success

    Strong Launches Position ELOCTATE & ALPROLIX for Future Success US launch Q2 2014, Japan Q1 2015, Canada Q1 2016 US launch Q2 2014, Japan Q3 2014, Canada Q4 2015 14% Total Market Share 13% 35% Total Market Share 12% 30% 31% 10% Japan 25% 10% 25% Launch = September US 2014 * Launch = July 2014 8% 20%

  31. Slide 31: Broad Reach Across Hemophilia Treatment Centers

    Broad Reach Across Hemophilia Treatment Centers, Opportunity to Drive Further Depth of Prescribing of HTCs* have PRESCRIBED 90% ALPROLIX to AT LEAST 1 PATIENT *123 of 136 hemophilia treatment centers (HTCs) of HTCs* have PRESCRIBED 90% ELOCTATE to AT LEAST 1 PATIENT *123 of 136 hemophilia treatment

  32. Slide 32: Opportunity Remains for Further Growth from Shift to Prophylaxis and EHL

    Opportunity Remains for Further Growth from Shift to Prophylaxis and EHL Therapies On Demand vs Prophylaxis Market Share of Patients on Prophylaxis (U.S.) 7% 18% Other EHL (Pegylated) Hemophilia A On Demand Prophylaxis 23% 50% 50% 100% 83% 70% Conventional (Short-Acting) Q2-14 Q2-15 Q2-16 2% Other E

  33. Slide 33: Plans to Expand to New Markets Where Already Approved or Filed

    Plans to Expand to New Markets Where Already Approved or Filed Launched in the  U.S. and Canada  Fully integrated  operation in Japan  with ~80 FTEs        BIVV approved / ELOCTATE and ALPROLIX Approved Elocta and ALPROLIX Approved filings accepted Not-yet-commercialized Territory Not-yet

  34. Slide 34: ELOCTATE has Delivered Strong Performance and Growth Opportunities Remain

    ELOCTATE has Delivered Strong Performance and Growth Opportunities Remain ELOCTATE Revenue ($mm) ELOCTATE Revenue ($M) Approved for Hem A to reduce frequency 500+ of bleeding episodes with prophylactic infusions every 3 to 5 days Advantage of more than two years of real- world experience and consist

  35. Slide 35: Evolution of the Hemophilia A Landscape

    Evolution of the Hemophilia A Landscape Near Term Longer Term Inhibitors Hemophilia A • Competition from other EHL entrants • Advancements in half-life extension technology including BIVV 001 • New MOAs including bispecific antibodies, RNAi therapeutics, gene therapies, etc. • Bypassing agents, ITI,

  36. Slide 36: ALPROLIX Has Also Delivered Strong Performance

    ALPROLIX Has Also Delivered Strong Performance and Growth Opportunities Remain ALPROLIX Revenue ($M) • Approved for Hem B to reduce frequency of 300+ bleeding episodes with prophylactic infusions every 7 to 10 days, with potential to extend dosing based on individual response 237 • Advantage of more

  37. Slide 37: Evolution of the Hemophilia B Landscape

    Evolution of the Hemophilia B Landscape Near Term Longer Term • Competition from other EHL entrants • Potential subcutaneous EHLs, including BIVV 002 • New MOAs including gene therapies, RNAi Strong Hemophilia Capitalized to Create 37 Integrated Capabilities Talented Team Confidential and proprietar

  38. Slide 38: Financial Overview

    Financial Overview John Greene, CFO

  39. Slide 39: Financial Snapshot

    Financial Snapshot Revenues ($M) Operating Income ($M) $631 $238 +63% POSITIVE $386 $32 2015 2016 2015 2016 Q1-Q3 Q1-Q3 Q1-Q3 Q1-Q3 Gross Margin 87% 79% Operating Margin 8% 38% Net Income ($M) Free Cash Flows ($M) $148 $203 POSITIVE POSITIVE $36 -$12 2015 2016 2015 2016 Q1-Q3 Q1-Q3 Q1-Q3 Q1-Q3 Tax R

  40. Slide 40: 2017 Financial Guidance

    2017 Financial Guidance Guidance GAAP Non-GAAP Opening Balance Sheet (In millions) Pro Forma Revenue * as of Sept 30, 2016 17 – 19% 17 – 19% Growth Total current assets $575.5 Cash and cash equivalents $325.0 Accounts receivable, net $126.8 Operating Margin 38 – 42% 43 - 47% Inventory $113.6 Other c

  41. Slide 41: Closing

    Bioverativ = Closing John Cox, CEO

  42. Slide 42: Our Commitment to the Hemophilia Community

    Our Commitment to the Hemophilia Community Humanitarian Aid Reaching Patients Worldwide 178 M 4,200 IUs of clotting People treated factor donated in 38 countries 4,600+ 300+ Surgeries, Acute bleeds 30 life-saving Percentage of pediatric patients receiving treatment in these countries has nearly doub

  43. Slide 43: A Unique and Compelling Investment Opportunity

    A Unique and Compelling Investment Opportunity Integrated Strong Hemophilia Capitalized to Talented team capabilities Franchise create value Confidential and proprietary 43

  44. Slide 44: Appendix

    Appendix

  45. Slide 45: Income Statement

    Income Statement 2016 2015 2015 2016 Pro Forma Nine months Nine months Nine months Full year Adjust end Sept 30 end Sept 30 end Sept 30 Revenues: Product, net 554.1 381.7 604.8 604.8 Collaboration revenue 6.2 4.4 26.4 26.4 Total revenues 560.3 386.1 631.2 631.2 Cost and expenses: Cost of sales 52.9

  46. Slide 46: GAAP/Non-GAAP reconciliation

    GAAP/Non-GAAP reconciliation Operating margin reconciliation: GAAP operating margin 38 - 42% One time separation and set up costs 2% Equity based compensation 2% Amortization of intangibles 1% Non-GAAP operating margin 43% - 47% Confidential and proprietary 46

  47. Slide 47: Balance Sheet

    Balance Sheet 2016 2015 2016 Pro Forma Nine months Nine months Full year Adjust end Sept 30 end Sept 30 Balance Sheet ASSETS Current assets: Cash 0.0 325.0 A 325.0 Accounts receivable, net 94.4 126.8 126.8 Inventory 252.1 283.3 (169.7) B 113.6 Other current assets 4.0 10.3 (0.2) C 10.1 Total current

  48. Slide 48: Sobi Collaboration

    Sobi Collaboration Rates post Sobi Opt-In Base Rate following Rate during the 1st commercial sale in Reimbursement Royalty and Net Revenue Share Rates: Method the Sobi Territory: Period: Sobi rate to Biogen on net sales in the Sobi Territory Royalty 12% Base Rate plus 5% Biogen rate to Sobi on net s

  49. Slide 49: Collaboration on San Raffaele's Lentiviral Platform for Hemophilia A and B

    Collaboration on San Raffaele’s Lentiviral Platform for Hemophilia A and B AAV Lentiviral Technology Leverages San Raffaele’s expertise in lentiviral vector development and next-generation lentiviral platform Integration Low Yes Safety, persistence Potential Clinical Profile Potential to provide sin

  50. Slide 50: Leading Medical Experts in Sickle Cell Disease and Research Stage Assets

    Leading Medical Experts in Sickle Cell Disease and a Portfolio of Research Stage Assets Technology Small molecule approaches primarily addressing the causative defect leading to the pathophysiology of SCD Potential Clinical Profile Goal is to develop disease-modifying therapies to treat significant

Bioverativ — Investor Day (January 2017) on 6ix